Wire · opportunities
FDA nod to first treatment for neurological symptoms of Type 3 Gaucher disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 November 2026 · Fusion42 review
The US FDA approved Infilbray (venglustat), the first drug targeting neurological symptoms of Type 3 Gaucher disease, designed to cross the blood-brain barrier and reduce harmful substance buildup in the brain.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 18 Nov 2026 and 22 Nov 2026.
◆ ◆ The Wire takeaway
Neurological symptoms of Type 3 Gaucher disease now have a drug treatment option, opening patient access and creating a market for therapies crossing the blood-brain barrier. You need to consider repositioning or developing treatments for rare neurological disorders with overlooked CNS involvement.
◆ Coverage
8 sources · first reported 18 Nov 2026 · latest 22 Nov 2026
◆ Related on Wire
◆ Topics